Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection (STERAL)
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study
Sponsor: Juan Macías
A PHASE4 clinical study on HCV Coinfection and HIV Infection, this trial is completed. The trial is conducted by Juan Macías and has accumulated 7 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Juan Macías
For direct contact, visit the study record on ClinicalTrials.gov .